158 related articles for article (PubMed ID: 26200284)
1. Bevacizumab in Combination with Chemotherapy or Molecularly Targeted Agents for Non-Small-Cell Lung Cancer with Brain Metastases.
Kim YH; Mishima M
J Thorac Oncol; 2015 Aug; 10(8):e76. PubMed ID: 26200284
[No Abstract] [Full Text] [Related]
2. Adding bevacizumab to chemotherapy effectively control radioresistant brain metastases in ALK-positive lung adenocarcinoma.
Su YL; Rau KM
J Thorac Oncol; 2015 Apr; 10(4):e21-2. PubMed ID: 25789840
[No Abstract] [Full Text] [Related]
3. Bevacizumab Plus Radiosurgery for Nonsquamous Non-Small Cell Lung Cancer Patients with Brain Metastases: Safe Combination?
Guinde J; Carron R; Tomasini P; Greillier L; Régis J; Barlesi F
World Neurosurg; 2017 Nov; 107():1047.e1-1047.e4. PubMed ID: 28803179
[TBL] [Abstract][Full Text] [Related]
4. Improving Treatment Options for Brain Metastases From ALK-Positive Non-Small-Cell Lung Cancer.
Wardak Z; Choy H
J Clin Oncol; 2016 Dec; 34(34):4064-4065. PubMed ID: 27863198
[No Abstract] [Full Text] [Related]
5. [Advances in Bevacizumab Therapy for Non-small Cell Lung Cancer
with Brain Metastases].
Qu L; Geng R; Song X
Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):515-8. PubMed ID: 27561800
[TBL] [Abstract][Full Text] [Related]
6. High-dose pemetrexed in combination with high-dose crizotinib for the treatment of refractory CNS metastases in ALK-rearranged non-small-cell lung cancer.
Gandhi L; Drappatz J; Ramaiya NH; Otterson GA
J Thorac Oncol; 2013 Jan; 8(1):e3-5. PubMed ID: 23242445
[No Abstract] [Full Text] [Related]
7. Bevacizumab in Combination with Platinum-Based Chemotherapy in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with or without Brain Metastases: A French Cohort Study (EOLE).
Bennouna J; Falchero L; Schott R; Bonnetain F; Coudert M; Ben Hadj Yahia B; Chouaid C
Oncology; 2018; 94(1):55-64. PubMed ID: 29065416
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study.
Besse B; Le Moulec S; Mazières J; Senellart H; Barlesi F; Chouaid C; Dansin E; Bérard H; Falchero L; Gervais R; Robinet G; Ruppert AM; Schott R; Léna H; Clément-Duchêne C; Quantin X; Souquet PJ; Trédaniel J; Moro-Sibilot D; Pérol M; Madroszyk AC; Soria JC
Clin Cancer Res; 2015 Apr; 21(8):1896-903. PubMed ID: 25614446
[TBL] [Abstract][Full Text] [Related]
9. Systemic Treatment of Brain Metastases.
Waqar SN; Morgensztern D; Govindan R
Hematol Oncol Clin North Am; 2017 Feb; 31(1):157-176. PubMed ID: 27912831
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy and Safety of Bevacizumab Combined with Chemotherapy as Second-line or Later-line Treatment in Advanced Nonsquamous Non-small Cell Lung Cancer].
Zheng X; Wang H; Zhang G; Yan X; Ma Z
Zhongguo Fei Ai Za Zhi; 2018 Jul; 21(7):513-518. PubMed ID: 30037370
[TBL] [Abstract][Full Text] [Related]
11. CNS Metastases in Patients With Non-Small-Cell Lung Cancer and ALK Gene Rearrangement.
Shi W; Dicker AP
J Clin Oncol; 2016 Jan; 34(2):107-9. PubMed ID: 26628475
[No Abstract] [Full Text] [Related]
12. Bevacizumab-Based Therapy for Patients with Brain Metastases from Non-Small-Cell Lung Cancer: Preliminary Results.
Zustovich F; Ferro A; Lombardi G; Farina P; Zagonel V
Chemotherapy; 2014; 60(5-6):294-9. PubMed ID: 25999127
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab and gefitinib enhanced whole-brain radiation therapy for brain metastases due to non-small-cell lung cancer.
Yang RF; Yu B; Zhang RQ; Wang XH; Li C; Wang P; Zhang Y; Han B; Gao XX; Zhang L; Jiang ZM
Braz J Med Biol Res; 2017 Nov; 51(1):e6073. PubMed ID: 29185589
[TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer.
Metro G; Chiari R; Ricciuti B; Rebonato A; Lupattelli M; Gori S; Bennati C; Castrioto C; Floridi P; Minotti V; Chiarini P; Crinò L
Expert Opin Pharmacother; 2015; 16(17):2601-13. PubMed ID: 26439599
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor blockade alters magnetic resonance imaging biomarkers of vascular function and decreases barrier permeability in a rat model of lung cancer brain metastasis.
Pishko GL; Muldoon LL; Pagel MA; Schwartz DL; Neuwelt EA
Fluids Barriers CNS; 2015 Feb; 12():5. PubMed ID: 25879723
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of Patients with ALK-positive Non-small Cell Lung Cancer
and Brain Metastases].
Lv J; Zhang Q; Qin N; Yang X; Zhang X; Wu Y; Li X; Zhang H; Wang J; Zhang S
Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):519-24. PubMed ID: 27561801
[TBL] [Abstract][Full Text] [Related]
17. [Combined multi-stage treatment of a patient with non-differentiated adenocarcinoma of the lungs with solitary brain metastasis].
Plandovskiĭ VA; Tarashkevich II; Shnitko SN; Anisimovets VN
Vopr Onkol; 1994; 40(4-6):235-7. PubMed ID: 7785252
[No Abstract] [Full Text] [Related]
18. Bevacizumab in Combination with Chemotherapy for Colorectal Brain Metastasis.
Finkelmeier F; You SJ; Waidmann O; Wolff R; Zeuzem S; Bähr O; Trojan J
J Gastrointest Cancer; 2016 Mar; 47(1):82-8. PubMed ID: 26714801
[TBL] [Abstract][Full Text] [Related]
19. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases.
Socinski MA; Langer CJ; Huang JE; Kolb MM; Compton P; Wang L; Akerley W
J Clin Oncol; 2009 Nov; 27(31):5255-61. PubMed ID: 19738122
[TBL] [Abstract][Full Text] [Related]
20. [Non-small-cell lung cancer].
Akita H; Kinoshita I
Gan To Kagaku Ryoho; 2008 May; 35(5):720-4. PubMed ID: 18487906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
